Immunohistochemistry: Definition, Uses, and Clinical Overview

Immunohistochemistry Introduction (What it is)

Immunohistochemistry is a laboratory method that uses antibodies to detect specific proteins in tissue samples.
It helps pathologists “label” cells so they can see what type of cells are present and what the cells are expressing.
It is commonly used in cancer care after a biopsy or surgery to support diagnosis and guide treatment planning.
It can also be used in some non-cancer conditions to classify inflammation or infection patterns.

Why Immunohistochemistry used (Purpose / benefits)

Immunohistochemistry is used because many diseases—especially cancers—can look similar under a standard microscope stain. Traditional pathology starts with routine staining (often hematoxylin and eosin, or H&E), which shows overall tissue structure and cell appearance. However, cell shape alone may not be enough to determine the exact cancer type, the likely site of origin, or which therapies may be relevant.

Immunohistochemistry helps solve several common clinical problems:

• Clarifying a diagnosis: It can distinguish between tumor types that resemble each other (for example, carcinoma vs lymphoma vs melanoma) by showing which proteins the tumor cells express.
• Classifying a cancer more precisely: Many cancers have subtypes that matter for prognosis (expected behavior over time) and for treatment selection.
• Identifying where a metastatic cancer started: When cancer is found in one organ but may have started elsewhere, Immunohistochemistry can provide clues about the primary site (the original location).
• Supporting staging and risk assessment: Some markers correlate with tumor biology, such as how quickly cells are dividing (proliferation).
• Guiding therapy selection: Certain protein markers are used to determine whether specific targeted therapies or immunotherapies might be considered. The implications vary by cancer type and stage.
• Improving communication across the care team: Results are typically reported in a standardized way, helping oncologists, surgeons, and radiation oncologists align on a plan.

Immunohistochemistry does not treat cancer. It is a diagnostic and decision-support tool that can influence the overall treatment pathway.

Indications (When oncology clinicians use it)

Immunohistochemistry is commonly used in situations such as:

• A new biopsy shows cancer, and the exact type needs confirmation or refinement.
• The tumor is poorly differentiated (cells look very abnormal), making the origin unclear on routine stains.
• A patient has metastatic cancer and the primary site is uncertain.
• The pathology report needs subtyping, such as distinguishing subtypes within breast, lung, prostate, colorectal, sarcoma, or gynecologic cancers (examples vary by clinician and case).
• The care team needs predictive biomarkers (markers that may help determine whether a therapy could be relevant), depending on the cancer type.
• There is a question of recurrence vs a new primary tumor.
• A blood or bone marrow disorder is suspected and tissue patterns need clarification (often alongside other tests).
• Tissue findings suggest infection, inflammatory disease, or autoimmune processes, where protein patterns can support a diagnosis.

Contraindications / when it’s NOT ideal

Immunohistochemistry is a test performed on tissue, so “contraindications” usually relate to sample limitations and interpretation challenges rather than patient safety. It may be less suitable or may require a different approach when:

• There is not enough tissue remaining from the biopsy to run reliable stains.
• The sample is poorly preserved (for example, delays in fixation or suboptimal fixation), which can weaken or distort staining.
• The tissue has extensive crush artifact, necrosis, or cautery damage, making results harder to interpret.
• The clinical question is better answered by molecular testing (such as gene mutations, fusions, or broader profiling), which Immunohistochemistry may not fully capture.
• The diagnosis requires flow cytometry (commonly for certain hematologic malignancies) because protein patterns on intact cells may be more informative than tissue staining alone.
• The most relevant target is an RNA or DNA change better assessed by in situ hybridization or sequencing.
• A prior treatment (such as chemotherapy or radiation) has altered the tumor’s appearance or marker expression, requiring cautious interpretation and sometimes repeat sampling.

In practice, Immunohistochemistry is often complementary—used alongside routine microscopy and other laboratory methods rather than replacing them.

How it works (Mechanism / physiology)

Immunohistochemistry works by using antibodies—proteins designed to bind to specific targets—to detect antigens, which are usually proteins inside or on the surface of cells.

At a high level:

• A tissue section is placed on a slide.
• An antibody is applied that binds to a specific protein of interest (for example, a marker associated with a tumor lineage or a therapy target).
• A detection system makes the antibody binding visible, often as a colored stain under the microscope.
• A pathologist interprets the pattern: which cells stain, where in the cell they stain (nucleus, cytoplasm, membrane), and how strong and widespread the staining is.

This is not a physiologic “mechanism of action” like a medication. Instead, it is a diagnostic pathway that links tumor biology to observable patterns:

• Tumor biology involved: cancers arise from different cell lineages (epithelial, lymphoid, melanocytic, mesenchymal), and these lineages often express characteristic proteins. Tumors also vary in receptor expression, proliferation, DNA repair protein expression, and immune microenvironment markers.
• Tissue involved: Immunohistochemistry is performed on tissue from biopsies or surgical specimens (and sometimes on cell blocks from fluid samples).
• Onset and duration: there is no onset in the body because nothing is administered to the patient. Clinically, turnaround time varies by laboratory workflow and the number of stains required.

Results are not always definitive on their own. Interpretation depends on the overall microscopic appearance, clinical context, and sometimes additional testing.

Immunohistochemistry Procedure overview (How it’s applied)

Immunohistochemistry is not a treatment procedure performed directly on a patient. It is a laboratory testing step applied to tissue obtained during clinical care. A typical high-level workflow in oncology looks like this:

1. Evaluation/exam: A clinician evaluates symptoms, physical findings, and history. Concern for cancer may arise from a lump, bleeding, weight loss, abnormal labs, or imaging findings (varies by cancer type and stage).
2. Imaging/biopsy/labs: Imaging may identify a suspicious area. A biopsy or surgical procedure collects tissue; blood tests may provide supportive context.
3. Staging: If cancer is found, additional imaging and pathology details help determine stage. Immunohistochemistry can contribute by clarifying tumor type and biomarkers used in staging frameworks for certain cancers.
4. Treatment planning: The pathology report—often including Immunohistochemistry—helps the care team discuss options such as surgery, radiation, systemic therapy, or combined approaches, depending on the diagnosis and stage.
5. Intervention/therapy: Treatment is delivered based on the overall plan. Immunohistochemistry itself is not an intervention.
6. Response assessment: Imaging, exams, tumor markers (when relevant), and sometimes repeat biopsy assess response. In some cases, additional Immunohistochemistry may be performed on new tissue if the cancer changes or returns.
7. Follow-up/survivorship: Ongoing monitoring may continue for years. Pathology details from the original diagnosis, including Immunohistochemistry, often remain important for future decisions.

From the patient perspective, Immunohistochemistry usually does not add a separate appointment. It is performed on tissue already collected, though additional tissue sampling may be needed if the original sample is insufficient.

Types / variations

Immunohistochemistry includes several practical variations, which may differ by lab, cancer type, and the clinical question:

• Diagnostic lineage panels: Groups of markers used together to determine what kind of tumor it is (for example, epithelial vs lymphoid vs melanocytic). Panels are used because no single marker is perfectly specific.
• Prognostic and proliferation markers: Markers that can reflect tumor behavior, such as proliferation activity. How these results are used varies by cancer type and reporting standards.
• Predictive biomarker testing: Markers used to help determine whether a particular category of therapy might be considered (for example, hormone receptors in some cancers, or immune-related markers in others). Clinical significance varies by tumor type and stage.
• Site-of-origin workups: When metastatic cancer is found, patterns of staining can support a likely primary site, combined with imaging and clinical history.
• Solid-tumor vs hematologic applications: Solid tumors often use Immunohistochemistry on formalin-fixed tissue sections. Hematologic malignancies may use it as part of a broader toolbox that can also include flow cytometry and genetic testing.
• Inpatient vs outpatient settings: The staining is done in the pathology lab; the patient setting depends on where the biopsy/surgery occurred.
• Adult vs pediatric care: The technique is similar, but marker selection and differential diagnoses differ in pediatric cancers.
• Single-stain vs multiplex approaches: Some labs use methods that evaluate multiple markers on one slide (technology and availability vary), which can be helpful for complex immune microenvironment questions.

Pros and cons

Pros:

• Helps confirm and refine cancer diagnosis beyond routine microscopy.
• Can differentiate look-alike tumors, reducing diagnostic uncertainty.
• Supports subtyping, which may affect prognosis and treatment planning.
• Can provide biomarker information relevant to certain therapies (varies by cancer type).
• Uses existing biopsy/surgical tissue in most cases, without additional procedures.
• Can be integrated with the overall pathology report for a clearer clinical picture.

Cons:

• Results can be affected by tissue quality and handling (fixation, necrosis, artifacts).
• Not all markers are fully specific; false positives/negatives can occur, so interpretation requires context.
• Some cases need multiple stains or repeat testing, which may lengthen the diagnostic workup.
• Limited tissue may force prioritization between Immunohistochemistry and other tests (for example, molecular profiling).
• Scoring and reporting can vary by marker and lab method, and may require expert review in complex cases.
• It generally detects proteins, not the full range of DNA/RNA alterations that can matter in oncology.

Aftercare & longevity

Because Immunohistochemistry is a laboratory test on tissue, there is no direct aftercare from the staining itself. The practical “aftercare” is usually about what happens after the biopsy or surgery and how results are used over time.

Factors that can affect the usefulness and longevity of Immunohistochemistry information include:

• Cancer type and stage: Some cancers rely heavily on Immunohistochemistry for classification and biomarker testing; others rely more on morphology or molecular testing. How the information influences care varies by cancer type and stage.
• Tumor biology and heterogeneity: A single tumor can contain regions with different marker expression. Small biopsies may not capture all variability.
• Quality of the specimen: Adequate tissue, prompt fixation, and careful processing improve reliability.
• Treatment effects over time: Marker expression can change after therapy or at recurrence, so older results may not fully reflect current disease biology.
• Follow-ups and coordination: Clear documentation and communication of results support continuity of care, including in survivorship and recurrence evaluations.
• Comorbidities and overall health: These do not typically change the Immunohistochemistry result, but they can influence which treatments are feasible if biomarkers suggest certain options.
• Access to specialized pathology services: Complex cases may benefit from subspecialty pathology review; availability varies by region and healthcare system.

Alternatives / comparisons

Immunohistochemistry is one part of diagnostic pathology. Alternatives and complements depend on the clinical question:

• Routine histology (H&E): The foundation of tissue diagnosis. H&E shows architecture and cell morphology, while Immunohistochemistry adds protein-expression “labels” that can clarify what the cells are.
• Special stains (non-antibody stains): Used for certain organisms, tissue components, or pigments. These can be faster for specific questions but are less targeted than Immunohistochemistry for tumor lineage and biomarkers.
• Flow cytometry: Often used for suspected lymphomas and leukemias because it measures multiple markers on individual cells in suspension. It can be more informative for some hematologic diagnoses, while Immunohistochemistry preserves tissue architecture.
• In situ hybridization (ISH/FISH): Detects specific DNA or RNA changes in tissue sections. This can be preferred when the key question involves gene amplification, rearrangements, or viral RNA/DNA, depending on the case.
• Molecular testing (PCR, NGS, broader profiling): Identifies mutations and other genetic alterations that Immunohistochemistry may not directly detect. Molecular testing may be used alongside or after Immunohistochemistry, especially when targeted therapy selection is being considered.
• Clinical and imaging follow-up (observation/active surveillance): In some low-risk or uncertain situations, clinicians may monitor rather than immediately pursue extensive testing. Whether this is appropriate varies by cancer type and stage.
• Repeat biopsy: If the tissue is insufficient, degraded, or discordant with the clinical picture, obtaining a new sample may be more useful than adding stains to a limited or poor-quality specimen.

These approaches are often combined. The most appropriate strategy is case-specific and depends on what clinical decision needs to be supported.

Immunohistochemistry Common questions (FAQ)

Q: Is Immunohistochemistry the same as a biopsy?
No. A biopsy is the procedure that removes tissue from the body. Immunohistochemistry is a lab test performed on that tissue to identify proteins that help classify the diagnosis.

Q: Does Immunohistochemistry hurt?
The staining itself does not affect the patient and does not cause pain. Any discomfort comes from the biopsy or surgery used to collect tissue, which varies by site and technique.

Q: Do I need anesthesia for Immunohistochemistry?
No anesthesia is needed for the lab test. Anesthesia or numbing medication may be used for the biopsy or surgery, depending on how the tissue is collected.

Q: How long does Immunohistochemistry take?
Turnaround time varies by laboratory, the number of stains needed, and whether the case requires additional review. Some cases are straightforward, while others need multiple marker panels and correlation with other tests.

Q: Is Immunohistochemistry safe?
For patients, it is generally considered safe because it is performed on tissue outside the body. Safety considerations mainly involve laboratory handling of chemicals and quality controls, managed by trained personnel.

Q: Can Immunohistochemistry be wrong?
Like any diagnostic test, it can have limitations. Results can be affected by tissue quality, technical factors, and marker specificity, which is why pathologists interpret Immunohistochemistry alongside the microscope appearance and clinical information.

Q: Will Immunohistochemistry tell me exactly what treatment I need?
It can provide information that supports treatment planning, especially when specific biomarkers are relevant. Treatment decisions typically depend on multiple factors, including cancer type, stage, overall health, and patient goals.

Q: What does it mean if a marker is “positive” or “negative”?
“Positive” usually means the tumor cells show detectable staining for that protein, while “negative” means they do not. The clinical meaning depends on the specific marker, how strongly and widely it stains, and the cancer type.

Q: How much does Immunohistochemistry cost?
Costs vary widely by healthcare system, insurance coverage, the number of stains ordered, and whether specialized testing is needed. Billing may appear as part of pathology charges from the biopsy or surgery.

Q: Does Immunohistochemistry affect fertility or pregnancy?
Immunohistochemistry itself does not affect fertility because it is performed on tissue in the lab. Fertility and pregnancy considerations are more often related to the cancer diagnosis and the treatments being considered, which vary by cancer type and stage.